Get the Stockscreener App
21.91
4.04%
0.85
After Hours:
21.89
-0.02
-0.09%
Rigel Pharmaceuticals stock is traded at $21.91, with a volume of 179.26K.
It is up +4.04% in the last 24 hours and up +17.10% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$21.06
Open:
$20.65
24h Volume:
179.26K
Relative Volume:
0.89
Market Cap:
$391.58M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-156.50
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+8.63%
1M Performance:
+17.10%
6M Performance:
+1.20%
1Y Performance:
+118.44%
1-Day Range:
$20.28
$22.03
1-Week Range:
$19.51
$22.03
52-Week Range:
$8.61
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
21.91 | 376.39M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
What is the dividend policy of Rigel Pharmaceuticals Inc. stockEarnings Report Opportunities To Watch Now - jammulinksnews.com
What makes Rigel Pharmaceuticals Inc. stock price move sharplyMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
Does Rigel Pharmaceuticals Inc. stock perform well during market downturnsEntry Signal Growth Plan For Every Investor - jammulinksnews.com
Why is Rigel Pharmaceuticals Inc. stock attracting strong analyst attentionTop Growth Planner That Work - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a growth stock or a value stockWealth Building Insights That Work - jammulinksnews.com
Why Rigel (RIGL) Could Beat Earnings Estimates Again - Yahoo Finance
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Are Investors Undervaluing Rigel Pharmaceuticals (RIGL) Right Now? - Yahoo Finance
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - BioSpace
Will Rigel Pharmaceuticals Inc. Benefit From Broader Market BounceLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Biotech Rigel Pharmaceuticals Reveals Q2 2025 Earnings Date: Key Financial Results Coming August 5 - Stock Titan
How Resilient Is Rigel Pharmaceuticals Inc. Stock During Economic DownturnsCommunity Strategy With High Win Rate Backtested - metal.it
Rigel Pharmaceuticals Inc. Recovery Likely Here’s What Data ShowsReal-Time Trade Insights Spark Market Reactions - metal.it
How does Rigel Pharmaceuticals Inc. generate profit in a changing economySuperior investment outcomes - jammulinksnews.com
What are the latest earnings results for Rigel Pharmaceuticals Inc.Invest smarter with expert stock recommendations - jammulinksnews.com
Should I hold or sell Rigel Pharmaceuticals Inc. stock in 2025Rapid growth trajectories - jammulinksnews.com
Is it the right time to buy Rigel Pharmaceuticals Inc. stockBuild a balanced portfolio for long-term success - jammulinksnews.com
What institutional investors are buying Rigel Pharmaceuticals Inc. stockSpectacular growth rates - jammulinksnews.com
How strong is Rigel Pharmaceuticals Inc. company’s balance sheetStay ahead with daily expert stock picks - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideBig Profit Small Risk Alerts - metal.it
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment - TipRanks
Will Rigel Pharmaceuticals Inc. stock benefit from AI tech trendsHigh-impact stock picks - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
What institutions are buying Rigel Pharmaceuticals Inc. stock nowHigh-margin investment plays - jammulinksnews.com
What analysts say about Rigel Pharmaceuticals Inc. stockStrongest growth potential - PrintWeekIndia
What drives Rigel Pharmaceuticals Inc. stock priceHigh-margin investment plays - Autocar Professional
Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership - simplywall.st
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks
Rigel Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
(RIGL) Proactive Strategies - news.stocktradersdaily.com
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):